GLP-1 receptor agonism
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
GLP-1 receptor agonists mimic the incretin hormone GLP-1. Activation increases glucose-dependent insulin secretion (so insulin rises mainly when glucose is high), slows the rate at which the stomach empties, and acts on central pathways that reduce appetite. This combination underpins their use in glucose control and weight management.
Peptides acting through this pathway
FAQ
What does glp-1 receptor agonism do?
GLP-1 receptor agonists mimic the incretin hormone GLP-1. Activation increases glucose-dependent insulin secretion (so insulin rises mainly when glucose is high), slows the rate at which the stomach empties, and acts on central pathways that reduce appetite. This combination underpins their use in glucose control and weight management.
Which peptides act through glp-1 receptor agonism?
Semaglutide, Liraglutide, Tirzepatide, Retatrutide. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit — a plausible pathway is a reason to study a compound, not evidence that it works in humans.
Mechanistic plausibility is not proof of clinical benefit. Research reference only — not medical advice.